// App-Quantinova.ai

BSH2020‐PO‐103 : Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON‐2 trial

Researchers

Presenter

  • T. Illidge

Principal Investigators

  • S. Iyer

  • N. Bartlett

  • W. S. Kim

  • D. Belada

  • T. Feldman

  • . Ills

  • E. Jacobsen

  • A. Httmann

  • P. L. Zinzani

  • O. O'Connor

  • P. McKay

  • W. Trepicchio

  • H. Miao

  • K. Fenton

  • M. Onsum

  • T. Manley

  • R. Advani

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Washington University School of Medicine, St. Louis, MO

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

  • John Theurer Cancer Center, Hackensack, NJ

  • Division of Haematology, Department of Internal Medicine, Faculty of Medicine, Debrecen, Hungary

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Surgery, University Hospital Essen, Essen, Germany

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Columbia University Medical Center, New York, NY

  • The Beatson, West of Scotland Cancer Centre, Glasgow,

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Seattle Genetics, Inc., Bothell, USA

  • Stanford University Cancer Institute, Stanford, CA

Locations

  • United Kingdom

  • United States

  • Czech Republic

  • Hungary

  • Germany

  • Italy

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Adult T-Cell Leukemia

  • Peripheral T-cell lymphoma

  • T-cell lymphoma

Biomarkers

  • Anaplastic lymphoma Kinase

  • Cluster of Differentiation 30

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Adcetris

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Vincristine

  • Doxorubicin

  • Prednisone

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved